Federal Medicaid spending through state-directed payments reached $93 billion annually across 41 states before the One Big Beautiful Bill Act took effect, with 84 percent benchmarked to commercial rates substantially above Medicare (KFF, June 2026). OBBBA caps those payments at 100 to 110 percent of Medicare depending on expansion status, severing the provider payment architecture embedded in capitation certifications for the July 2026 rating period that MCO actuaries are now repricing in real time.

The rate certifications the CMS 2026-2027 Managed Care Rate Development Guide governs are not easily undone. They embed provider payment assumptions, population morbidity, pharmacy trend, and cost-sharing structures as of the certification date, and they are designed to hold for a twelve-month rating period. OBBBA breaks that design simultaneously on three fronts: semiannual eligibility redeterminations beginning December 31, 2026 will rotate expansion adults off Medicaid rolls at rates no certified population projection assumed; state-directed payment caps are already forcing states to renegotiate SDP preprints that underpinned those rates; and GLP-1 pharmacy trend for the expansion population is in motion. All three disruptions arrive within a single certified rate period, without a corresponding mechanism for mid-cycle recovery.

The SDP Financing Architecture and the Rate Certification Assumption

State-directed payments are not a marginal mechanism. Across 42 states with Medicaid managed care contracts, 41 had SDPs in place as of 2026, channeling $137 billion annually in combined state and federal spending, with the federal share reaching $93 billion and $78 billion of that directed to hospital services (KFF, June 2026). The leading states illustrate how concentrated the exposure is: California directed $10.6 billion in annual federal SDP spending, Texas $6.3 billion, North Carolina $5.2 billion, and Illinois $5.1 billion. The benchmark for nearly all of that spending was average commercial rates; KFF found that 84 percent of the $93 billion federal total was set relative to commercial benchmarks. Medicare hospital payment rates consistently fall 15 to 40 percentage points below commercial rates depending on service category and state. OBBBA's cap at 100 to 110 percent of Medicare cuts directly into the layer in those high-concentration states.

A 2024 CMS rule compounded the structural dependency. Before that rule, states could direct supplemental payments to providers through separate mechanisms outside the capitation structure. The 2024 rule required states to incorporate all SDP pass-throughs into capitation rates, making those pass-throughs a documented component of the actuarially certified rate. The reform improved transparency; it also created a direct chain between the SDP preprint, the capitation certification, and the soundness opinion. When OBBBA caps the SDP at a lower rate than the preprint assumed, the capitation component built on that preprint is now above the legally permissible amount. For the July 2026 rating period, certifications reflecting pre-OBBBA commercial rate benchmarks may contain embedded SDP pass-throughs that exceed what state SDP programs can legally pay under the new statute.

The Soundness Standard Under Mid-Cycle Stress

Actuarial soundness under 42 CFR 438.4 requires that capitation rates be projected to provide for all reasonable, appropriate, and attainable costs required under the terms of the MCO contract for the time period and population covered. The time period language is the operative phrase: a rate certified as actuarially sound in April 2026 for a July 2026 through June 2027 rating period carries that certification through the end of the period, absent material intervening circumstances that trigger a formal amendment process.

Mid-period adjustments are possible but narrow. States may modify capitation rates during a rating period, but changes exceeding 1 percent of the certified rate require a complete actuarial re-certification filed as a contract amendment subject to CMS review. That process adds months of lag between recognizing an adequacy problem and implementing a rate correction. For an MCO that discovers mid-year that its SDP pass-through revenue has been cut by a statutory cap, the only near-term adjustment available under the 1 percent rule is marginal. A large SDP exposure in a state where the cap applies immediately cannot be recovered through the available regulatory mechanism without a full re-certification that the mid-year operational timeline cannot comfortably absorb.

This is where the OBBBA sequence differs from ordinary medical trend variance. Cost trend deterioration that materializes mid-year is within the range of outcomes an actuarially sound rate is required to accommodate. A statutory change that eliminates or reduces a specific payment mechanism after a rate has been certified is a different class of disruption. Medicaid managed care has not previously operated in an environment where the provider payment architecture changed materially within an active rating period through post-certification legislation of this scale. The $840.2 billion in total CBO-scored Medicaid spending reductions over ten years (Congressional Budget Office, 2025) positions OBBBA as a structural shift, not a policy adjustment around the margins.

Two Undefined Terms

OBBBA includes a grandfathering provision intended to give ongoing SDP programs a phase-down transition rather than an immediate cut. SDPs sufficiently advanced as of enactment can continue at rates above the Medicare cap until January 1, 2028, when a 10-percentage-point annual phase-down begins. The qualification depends on two terms CMS has not yet formally defined: "good faith effort" and "completed preprint." A state with a hospital SDP preprint in active development at the time of OBBBA's enactment may claim grandfathered status if the preprint was sufficiently complete to constitute a "completed preprint," or if the state made a "good faith effort" toward completion before the statute's effective date.

For certifying actuaries, this ambiguity creates a documentation problem with no clean resolution. The actuarial memorandum for a 2026-2027 rate filing that incorporates SDP pass-throughs must now either assume grandfathered status, assume non-grandfathered status, or explicitly bracket the rate as contingent on CMS guidance that has not arrived. None of those paths produces a clean soundness opinion under the standard 42 CFR 438.4 framework. MACPAC has noted that "the absence of data on actual directed payment amounts at the provider level limit the ability for stakeholders to assess how these directed payments may relate to specific state policy goals" (MACPAC). That data gap predates OBBBA; the grandfathering ambiguity layers another source of uncertainty onto an already opaque component of the capitation structure.

The timing compounds the problem. The CMS 2026-2027 Managed Care Rate Development Guide was released in February 2026, before the OBBBA provisions crystallized into their enacted form (CMS, February 2026). The guide provides the framework for developing actuarially sound rates for rating periods beginning July 1, 2026, but it does not address how certifying actuaries should treat SDP components whose grandfathering status depends on federal guidance not yet issued. The July 2026 rating period is not waiting for that guidance. Certifications are being finalized now, and MCO actuaries are navigating the ambiguity without a regulatory safe harbor. The practical response is explicit scenario documentation: certify the rate under the best-estimate assumption about grandfathering status, identify the range of outcomes if that assumption proves wrong, and ensure the actuarial memorandum contains language that would allow a mid-year amendment to be processed quickly if CMS guidance resolves the question adversely.

Semiannual Redeterminations and the Adverse Selection Arithmetic

The OBBBA provision with the most direct effect on mid-cycle capitation adequacy is the semiannual eligibility redetermination requirement for Medicaid expansion adults, effective for renewals scheduled on or after December 31, 2026. The Urban Institute projects that semiannual redeterminations alone would reduce Medicaid expansion enrollment by 2.0 to 3.1 million individuals in 2028, a 10.7 to 17.0 percent reduction from the 18.2 million average monthly expansion enrollment baseline, depending on how well states implement best-practice retention procedures (Urban Institute, 2026).

The morbidity implication is not symmetric. Eligibility redeterminations do not remove members randomly from the risk pool. Lower-acuity members near the Medicaid income eligibility threshold are more likely to be found ineligible for income reasons or to be procedurally disenrolled through administrative friction. Under current state administrative benchmarks, approximately 11 percent of expansion adults facing redetermination are procedurally disenrolled: not found ineligible, but lost because they did not respond to renewal notices in time (Urban Institute, 2026). Members who navigate administrative processes reliably tend to be residentially stable, more engaged with the health system, and generally healthier. Members with complex chronic conditions, behavioral health diagnoses, or long-term services and supports dependencies are less likely to inadvertently interrupt their own coverage through inaction. Those members stay enrolled; the healthier, more mobile population cycles out faster.

The actuarial consequence runs forward through the rating period. As semiannual redeterminations begin rotating through an MCO's expansion book starting December 2026, the surviving enrolled population carries higher average morbidity than the population the July 2026 capitation certification assumed. That morbidity drift is not priced into the certified rate. If the acuity shift is material by the first quarter of 2027, the MCO's per-member per-month claims experience will diverge from the embedded cost assumptions without a mechanism for mid-period rate recovery within the 1 percent adjustment ceiling. The dynamic is the same adverse selection mechanics that drove the post-2014 ACA actuarial instability, compressed into a six-month cycle rather than an annual one, and operating on a Medicaid population where the clinical complexity of the retaining cohort is higher on average than in the individual market.

Plan Exits and Concentration Risk

The Big Five Medicaid MCOs reported net enrollment declines of 1.4 million, or 3.8 percent, from 36.2 million to 34.8 million since H.R. 1 was enacted at the end of Q2 2025 (Georgetown Center for Children and Families, May 2026). Several smaller plans have already moved: UCare announced plans to exit all Medicaid business, and PacificSource withdrew from Lane County, Oregon effective January 2026. These exits concentrate remaining enrollment in fewer plans in states where MCO market structure is already limited, and they signal that plan participation decisions are now being driven partly by actuarial adequacy concerns under the new legislative environment.

The actuarial problem with plan exits extends beyond the exiting plan's own rate adequacy. When a plan exits mid-cycle, its enrolled population must transfer to remaining plans at those plans' certified capitation rates. If the exiting plan had disproportionately attracted lower-acuity expansion adults through plan design or network design, the remaining plans absorb a transferred population that is less healthy than their certified rate assumed, without any mid-period compensation. States with the highest SDP concentrations face the most acute version of this risk: California and Texas together account for $16.9 billion in annual federal SDP spending, and any plan exit in those markets would redistribute a large, potentially high-acuity block at rates that were not built for the transferred mix. Notably, 81 percent of SDPs above Medicare rates are currently financed wholly or partly through intergovernmental transfers and provider taxes (KFF, June 2026), a financing structure OBBBA also restricts by banning new provider taxes in expansion states. That restriction compounds the budget pressure on the states most exposed to plan exit risk.

Pharmacy Trend and the GLP-1 Layer

The 2026-2027 capitation certifications carry a pharmacy trend assumption built on a Medicaid expansion population with specific GLP-1 coverage scope. Most state Medicaid programs, as of the time those rates were developed, covered GLP-1 medications primarily for diabetes management and excluded obesity-indication treatment. CMS launched the BALANCE model in 2026 to expand GLP-1 access in Medicaid managed care on a voluntary basis. An MCO whose certified pharmacy trend assumed a pre-BALANCE exclusion, and which then faces operational or contractual pressure to extend obesity-indication GLP-1 coverage, now carries a mid-period pharmacy trend risk not reflected in the capitation rate. The drug pricing for branded GLP-1s remains above $800 per month even after PBM rebates for most commercial populations, and the Medicaid net-of-rebate prices, while lower under mandatory rebate statutes, still represent a material per-member cost for a population with a high obesity prevalence.

OBBBA also includes PBM reform provisions that restructure pharmacy benefit management for Medicaid plans, including pass-through pricing requirements that alter how pharmacy costs flow through MCO capitation versus direct fee-for-service components. The mechanics interact with GLP-1 trend in a directionally unfavorable way: higher-priced drugs flowing through a more transparent pass-through structure produce a higher and more visible pharmacy cost per member than a spread-model alternative. Actuaries building pharmacy trend for 2026-2027 are working with a population that is simultaneously shrinking through redeterminations, potentially expanding GLP-1 coverage through BALANCE, and operating under a structurally changed PBM channel. Those three effects compound in the same direction on per-member pharmacy cost. The CMS rate guide requires trend factors to be "developed from actual experience of the Medicaid population or a similar population in accordance with generally accepted actuarial practices and principles" (CMS, February 2026). When the population is in legislative flux, the historical experience base becomes less reliable as a forward proxy, and trend selection requires explicit scenario analysis and documentation of the limitations.

Why This Matters

The OBBBA mid-cycle certification problem is structural, not a short-term administrative friction. The 42 CFR 438.4 soundness framework was built for a world where provider payment structures, eligibility criteria, and pharmacy policy change incrementally between rate periods, not simultaneously within one. MCOs that entered the July 2026 rating period with heavy SDP dependence in high-concentration states, expansion enrollment profiles that skew toward lower-acuity working-age adults, and pharmacy trend assumptions built on a pre-BALANCE GLP-1 coverage policy face a compounding rate adequacy risk. The three exposures do not add linearly: a higher-acuity retained population drives both inpatient trend and pharmacy trend upward, while the SDP cap reduces the capitation revenue that would otherwise offset those cost increases.

From reviewing actuarial certifications for Medicaid MCOs in states with large state-directed payment programs, the consistent pattern when directed payment mechanisms are abruptly capped mid-cycle is that rate certifications become contested documents between the MCO, the state, and CMS. Actuaries end up working between conflicting soundness interpretations, with the certifying actuary caught between an MCO claiming inadequacy and a state claiming the certified rate remains sound under the current contract. The OBBBA creates that situation simultaneously in 41 states, on a compressed timeline, with CMS guidance on grandfathering still pending. Certifying actuaries working on mid-year amendments or recontracting exercises should build an explicit adequacy bridge: which SDP preprints have been adjudicated for grandfathering, which remain pending CMS guidance, what the capitation rate assumes under each scenario, and what morbidity trajectory the enrolled population shows as December redeterminations begin to take effect. That is not a standard certification exhibit, but it is the documentation that matches the information environment actuaries are actually operating in for the 2026-2027 period.

Carriers that treat the July 2026 certification as settled because it was finalized before OBBBA's implementation provisions crystallized fully will surface the gap in claims experience: higher inpatient costs from the higher-acuity population retained through adverse selection, pharmacy trend above projection from GLP-1 expansion, and SDP pass-through shortfalls the certified rate does not recover. The actuarial response is not to wait for CMS implementation guidance before beginning this analysis. It is to build the adequacy scenarios now, document the assumptions explicitly, and have the briefing ready for the state before the gap widens past the 1 percent adjustment threshold.

Further Reading

Sources